Bronchiectasis Clinical Trial
Official title:
Investigation of the Efficiency of Pulmonary Rehabilitation With Telerehabilitation Method in Patients With Bronchiectasis
Verified date | November 2023 |
Source | Saglik Bilimleri Universitesi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is to determine the effectiveness of pulmonary rehabilitation by telerehabilitation method in bronchiectasis patients. The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TRGr) and Control Group (CGr).
Status | Completed |
Enrollment | 35 |
Est. completion date | June 4, 2024 |
Est. primary completion date | March 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged 18 and over - Diagnosed with bronchiectasis by HRCT - Stable clinical state at the time of admission without infection or exacerbation in the previous 3 weeks - Know how to use technological devices Exclusion Criteria: - A history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training - Patients with systemic diseases other than bronchiectasis that also affect the lungs, such as systemic lupus erythematosus, infection, interstitial lung disease, lung cancer, heart and kidney failure, which will cause shortness of breath - Having balance problems that prevent them from doing exercises - Participation in a pulmonary rehabilitation program within the past 12 months |
Country | Name | City | State |
---|---|---|---|
Turkey | Saglik Bilimleri University | Istanbul | Uskudar |
Lead Sponsor | Collaborator |
---|---|
Saglik Bilimleri Universitesi |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The exercise capacity | The exercise capacity will be assessed by the incremental shuttle walking test. | Change from baseline incremental shuttle walking distance at 8 weeks | |
Secondary | Forced vital capacity (FVC) | Forced vital capacity will be assessed by the spirometer. Pulmonary function test will performe by using the Pony Fx spirometry device, and according to the American Thoracic Society (ATS) guidelines | Change from baseline FVC at 8 weeks | |
Secondary | Forced expiratory volume in one second (FEV1) | Forced expiratory volume in one second will be assessed by the spirometer. Pulmonary function test will performe by using the Pony Fx spirometry device, and according to the American Thoracic Society (ATS) guidelines | Change from baseline FEV1 at 8 weeks | |
Secondary | Respiratory muscle strength | Respiratory muscle strength will be evaluated by the intraoral pressure measurement device.The mouth pressure measurement was performed with the Cosmed Pony Fx. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely, and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated five times. Verbal or visual feedback was provided after each maneuver. The aim is that the variability between measurements is less than 10 cm H2O. The maximum value was obtained. | Change from baseline respiratory muscle strength at 8 weeks | |
Secondary | Peripheral muscle strength | Peripheral muscle strength will be assessed by the hand held dynamometer | Change from baseline peripheral muscle strength at 8 weeks | |
Secondary | Perception of dyspnea | Perception of dyspnea will be evaluated by Modified Medical Research Council Dyspnea scale. The mMRC Dyspnea Scale is best used to establish baseline functional impairment due to dyspnea attributable to respiratory disease; tracking the mMRC over time or with therapeutic interventions is of less certain clinical utility.The severity of dyspnea is rated on a scale of 0 to 4. "O" means no dyspnea perception, "4" means severe dyspnea perception. | Change from baseline dyspnea perception at 8 weeks | |
Secondary | Saint George Respiratory Questionnaire (SGRQ) score | The quality of life will be assessed by the Saint George Respiratory Questionnaire.The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life) | Change from baseline SGRQ score at 8 weeks | |
Secondary | Modified Borg Scale | Exertion and rest define the level of dyspnea. It consists of ten items that describe the severity of dyspnea according to its degree. A minimum of 1 and a maximum of 10 points can be obtained. 1, no shortness of breath. 10, maximal shortness of breath. | Change from baseline Modified Borg Scale score at 8 weeks | |
Secondary | Leicester Cough Questionnaire (LCQ) | The cough will be assessed by the Leicester Cough Questionnaire. It includes physical, psychological and social sub-parameters and each item is scored between 1-7. High scores indicate that the cough is less affected, while low scores indicate that the cough is more affected. | Change from baseline LCQ score at 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05034900 -
Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis?
|
N/A | |
Recruiting |
NCT04101448 -
Prevalence of Bronchiectasis in COPD Patients
|
||
Withdrawn |
NCT03376204 -
Pain Mechanisms in Patients With Bronchiectasis
|
||
Completed |
NCT02550821 -
Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects
|
||
Completed |
NCT02656992 -
Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis
|
N/A | |
Completed |
NCT02048397 -
Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02282202 -
Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD
|
N/A | |
Recruiting |
NCT01761214 -
Bacteriology and Inflammation in Bronchiectasis
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Completed |
NCT01578681 -
ELTGOL and Bronchiectasis. Respiratory Therapy
|
N/A | |
Completed |
NCT01854788 -
3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT00769119 -
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
|
Phase 2 | |
Terminated |
NCT00524095 -
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
|
Phase 2 | |
Completed |
NCT01117493 -
Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Completed |
NCT00656721 -
Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients
|
N/A | |
Completed |
NCT04081740 -
Biological Determinants of Sputum Rheology in Chronic Airway Diseases
|
||
Enrolling by invitation |
NCT02546297 -
Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis
|
Phase 4 | |
Completed |
NCT03628456 -
Effect of HFCWO Vests on Spirometry Measurements
|
N/A |